USPTO serial 99012197
SYTHEIA
Reviewed by CopyMark Law Group
Status 616
- Filing date
- Status date
- Registration date
- —
- Examiner
- CLONCH, ABIGAIL
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SYTHEIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Malvern, PA, US
Malvern, PA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Don Cha
Don Cha HDC INTELLECTUAL PROPERTY LAW, LLP14405 W Colfax AveSTE 305Lakewood, CO 80401Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Gene therapy products, namely, genetically engineered tissues for transplant purposes; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; Gene therapy products, namely, rAAV vector for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases; Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant DNA for treating ocular diseases; Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa; Gene therapy products, namely, rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 4, 2026 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Oct 4, 2026 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Oct 4, 2026 | PETG | PETITION TO REVIVE-GRANTED | — |
| Oct 4, 2026 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Mar 31, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 19, 2026 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Aug 12, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Aug 12, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 12, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 6, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 3, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 30, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 18, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 18, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 18, 2025 | NWAP | NEW APPLICATION ENTERED | — |